hlg-20250331

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 001-40209

Heliogen, Inc.

(Exact name of registrant as specified in its charter)


Delaware			85-4204953
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
130 West Union Street, Pasadena, California			91103
(Address of Principal Executive Offices)			(Zip Code)

Registrant's telephone number, including area code: (626) 720-4530

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.0001 par value per share

HLGN

OTCQX

Warrants, each 35 warrants exercisable for one share of common stock at an exercise price of $402.50 per share

HLGNW

OTCPK

Preferred Share Purchase Rights

N/A

OTCQX

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

As of April 30, 2025, the registrant had 6,129,942 shares of common stock, par value $0.0001 per share outstanding.

Table of Contents


			Page
Cautionary Note Regarding Forward-Looking Statements			3
Part I - Financial Information
Item 1. Financial Statements
Consolidated Balance Sheets			5
Consolidated Statements of Operations			6
Consolidated Statements of Comprehensive Loss			7
Consolidated Statements of Stockholders’ Equity (Deficit)			8
Consolidated Statements of Cash Flows			9
Notes to Unaudited Consolidated Financial Statements			11
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			22
Item 3. Quantitative and Qualitative Disclosures About Market Risk			26
Item 4. Controls and Procedures			26
Part II - Other Information
Item 1. Legal Proceedings			28
Item 1A. Risk Factors			28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			28
Item 3. Defaults Upon Senior Securities			28
Item 4. Mine Safety Disclosures			28
Item 5. Other Information			28
Item 6. Exhibits			29
Signatures			30

Table of Contents

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. All statements, other than statements of present or historical fact included in this Quarterly Report regarding our future financial performance, as well as our strategy, future operations, financial position, estimated revenues, losses, projected costs, prospects, plans and objectives of management are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative of such terms or other similar expressions. These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Although we believe such expectations and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. All readers are cautioned that the forward-looking statements contained in this Quarterly Report are not guarantees of future performance and we cannot assure any reader that such statements will be realized or that the forward-looking events and circumstances will occur.

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

•our ability to fund our future cash obligations and continue as a going concern;

•our ability to access sources of capital to finance our operations and future capital requirements;

•our ability to explore and execute on strategic transactions;

•our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder;

•our ability to implement changes to our business strategy and future operations;

•changes in our financial position, estimated revenues and losses, projected costs, prospects and plans;

•our ability to execute our business model, including market acceptance of our planned products and services;

•changes in domestic and foreign business, market, financial, political, legal conditions and applicable laws and regulations;

•our ability to grow market share in our existing markets or any new markets we may enter;

•our ability to achieve and maintain profitability in the future;

•our ability to maintain and enhance our products and brand, and to attract and retain customers;

•our ability to find new partners for product and service offerings;

•the success of our strategic relationships with third parties;

•our ability to scale in a cost-effective manner;

•developments and projections relating to our competitors and industry;

•our ability to protect and commercialize our intellectual property;

•the actions of our stockholders and the related impact on the price of our common stock;

Table of Contents

•expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended;

•our ability to find and retain critical employee talent and key personnel;

•our ability to successfully manage changes in our executive team;

•the possibility that we may be adversely impacted by other economic, business, and/or competitive factors;

•future exchange and interest rates;

•the outcome of any known and unknown litigation and regulatory proceedings; and

•other risks and uncertainties, including those disclosed under “Item 1A. Risk Factors” contained in Part I of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2025 and the risk factors and other cautionary statements contained in other filings that have been made or will be made with the SEC by the Company.

Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Should one or more of the risks or uncertainties described in this Quarterly Report, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Our SEC filings are available publicly on the SEC’s website at www.sec.gov.

You should read this Quarterly Report with the understanding that our actual future results, levels of activity and performance as well as other events and circumstances may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Table of Contents

Part I - Financial Information

Item 1. Financial Statements

Heliogen, Inc.

Consolidated Balance Sheets

($ in thousands, except share data)

(Unaudited)


	March 31, 2025		December 31, 2024
ASSETS
Cash and cash equivalents	$	30,064	$	36,949
Short-term restricted cash	—		500

Receivables, net	179		764

Prepaid and other current assets	1,160		865
Total current assets	31,403		39,078
Operating lease right-of-use assets	146		2,831
Property, plant and equipment, net	137		315

Long-term restricted cash	—		1,000
Other long-term assets	998		1,066
Total assets	$	32,684	$	44,290
LIABILITIES AND STOCKHOLDERS’ EQUITY
Trade payables	$	1,170	$	1,450
Accrued expenses and other current liabilities	7,401		11,164


Total current liabilities	8,571		12,614
Operating lease liabilities, non-current	730		2,314

Other long-term liabilities	354		344
Total liabilities	9,655		15,272
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares outstanding as of March 31, 2025 and December 31, 2024	—		—
Common stock, $0.0001 par value; 500,000,000 shares authorized; 6,116,752 and 6,096,084 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	1		1
Additional paid-in capital	435,556		435,159
Accumulated other comprehensive loss	(538)		(511)
Accumulated deficit	(411,990)		(405,631)
Total stockholders’ equity	23,029		29,018
Total liabilities and stockholders’ equity	$	32,684	$	44,290

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Operations

($ in thousands, except per share and share data)

(Unaudited)


	Three Months Ended
	March 31,
		2025		2024
Revenue:
Services revenue		$	—	$	954
Grant revenue		—		574
Total revenue		—		1,528
Cost of revenue:
Cost of services revenue (including depreciation)		—		903
Cost of grant revenue		—		574

Total cost of revenue		—		1,477
Gross profit		—		51

Operating expenses:
Selling, general and administrative		4,638		12,355
Research and development		1,088		3,791
Impairment and other charges		1,155		32
Total operating expenses		6,881		16,178
Operating loss		(6,881)		(16,127)

Interest income		300		683
Loss on warrant remeasurement		(3)		(24)
Other income, net		227		245
Net loss before taxes		(6,357)		(15,223)
Provision for income taxes		(2)		(2)
Net loss		$	(6,359)	$	(15,225)

Loss per share:
Loss per share – Basic and Diluted		$	(1.03)	$	(2.53)
Weighted-average number of shares outstanding – Basic and Diluted		6,170,087		6,020,992

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Comprehensive Loss

($ in thousands)

(Unaudited)


	Three Months Ended
	March 31,
		2025		2024
Net loss		$	(6,359)	$	(15,225)
Other comprehensive loss, net of taxes:
Unrealized gains on available-for-sale securities		—		1
Cumulative translation adjustment		(27)		(2)
Total other comprehensive loss, net of taxes		(27)		(1)
Comprehensive loss		$	(6,386)	$	(15,226)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Stockholders’ Equity (Deficit)

($ in thousands, except share data)

(Unaudited)


		Three Months Ended March 31, 2025
	Common Stock		Additional Paid-in Capital			Accumulated Other Comprehensive Loss		Accumulated Deficit		Total
		Shares			Amount
Balance as of December 31, 2024		6,096,084	$	1		$	435,159	$	(511)	$	(405,631)	$	29,018
Net loss		—	—			—		—		(6,359)		(6,359)
Other comprehensive loss		—	—			—		(27)		—		(27)
Share-based compensation		—	—			406		—		—		406

Vesting of restricted stock units		31,205	—			—		—		—		—
Tax withholding related to vesting of restricted stock units		(10,537)	—			(9)		—		—		(9)





Balance as of March 31, 2025		6,116,752	$	1		$	435,556	$	(538)	$	(411,990)	$	23,029


		Three Months Ended March 31, 2024
	Common Stock		Additional Paid-in Capital			Accumulated Other Comprehensive Loss		Accumulated Deficit		Total
		Shares			Amount
Balance as of December 31, 2023		5,946,315	$	1		$	430,678	$	(516)	$	(438,178)	$	(8,015)
Net loss		—	—			—		—		(15,225)		(15,225)
Other comprehensive loss		—	—			—		(1)		—		(1)
Share-based compensation		—	—			1,286		—		—		1,286

Vesting of restricted stock units		35,382	—			—		—		—		—
Tax withholding related to vesting of restricted stock units		(11,324)	—			(17)		—		—		(17)




Vesting of warrants issued in connection with customer agreements		—	—			51		—		—		51
Balance as of March 31, 2024		5,970,373	$	1		$	431,998	$	(517)	$	(453,403)	$	(21,921)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)


	Three Months Ended
	March 31,
	2025		2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(6,359)	$	(15,225)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24		446
Impairment charges	861		—

Share-based compensation	406		1,286
Change in fair value of warrants	3		24

Deferred income taxes	2		2
Non-cash operating lease expense	330		458
Other non-cash operating activities	(375)		(119)
Changes in assets and liabilities:
Receivables, net	529		(1,331)
Inventories, net	—		133
Prepaid and other current assets	(307)		(1,147)
Trade payables and accrued liabilities	(3,236)		135
Contract liabilities	—		1,308
Change in contract loss provisions, net	—		(824)
Other non-current assets and liabilities	(308)		541
Net cash used in operating activities	(8,430)		(14,313)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	—		(150)
Proceeds from sale of property, plant and equipment	54		—

Maturities of available-for-sale securities	—		10,000



Net cash provided by investing activities	54		9,850
CASH FLOWS FROM FINANCING ACTIVITIES:


Payment related to taxes for net-share settlement of share-based compensation	(9)		(17)



Net cash used in financing activities	(9)		(17)
Decrease in cash, cash equivalents and restricted cash	(8,385)		(4,480)
Cash, cash equivalents and restricted cash at the beginning of the period	38,449		64,215
Cash, cash equivalents and restricted cash at the end of the period	$	30,064	$	59,735

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Cash Flows (continued)

($ in thousands)

(Unaudited)


	Three Months Ended
	March 31,
	2025		2024
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	30,064	$	58,235
Short-term restricted cash	—		500
Long-term restricted cash	—		1,000
Total cash, cash equivalents and restricted cash	$	30,064	$	59,735



Non-cash investing and financing activities:
Fair value of Project Warrants recognized in equity	$	—	$	51
Capital expenditures incurred but not yet paid	$	—	$	65

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Note 1—Organization and Basis of Presentation

Background

Heliogen, Inc. and its subsidiaries (collectively, “Heliogen” or the “Company”), is a renewable energy technology company focused on delivering round-the-clock, low-carbon energy production, using concentrated sunlight and thermal energy storage to deliver cost-effective, load-following, high-capacity factor thermal and electric energy. Unless otherwise indicated or the context requires otherwise, references in our unaudited consolidated financial statements to “we,” “us,” or “our” and similar expressions refer to Heliogen.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, these unaudited consolidated financial statements do not include all information or notes required by GAAP for annual financial statements. In the opinion of management, the unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary for fair statement.

The results reported in these unaudited consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year. These unaudited consolidated financial statements should be read in conjunction with the annual financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Annual Report”), filed with the Securities and Exchange Commission on March 27, 2025.

Certain immaterial prior period amounts, such as severance costs, have been reclassified to conform to current period presentation. These changes did not have a material impact on our financial position or results of operations.

Liquidity and Going Concern

These financial statements have been prepared assuming the Company will continue as a going concern. This basis of accounting contemplates continuity of operations, realization of assets and satisfaction of liabilities and commitments in the normal course of business. These financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

As of March 31, 2025, the Company had liquidity of $30.1 million, consisting of cash and cash equivalents and no debt. During the three months ended March 31, 2025, the Company incurred a net loss of $6.4 million and used cash in operations of $8.4 million. The Company expects to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on these factors, the Company anticipates that it may not have sufficient resources to fund its cash obligations for the next 12 months after the issuance date of the unaudited consolidated financial statements, which raises substantial doubt about the Company’s ability to continue as a going concern. The Company has evaluated the conditions discussed above and is taking various steps in an effort, to alleviate them, including the following actions.

In the second quarter of 2024, the Company made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of the Company’s manufacturing facility in Long Beach, California, (the “Manufacturing Facility”) and a reduction in third-party costs. In February 2025, we terminated the lease for the Manufacturing Facility. These actions were intended to further reduce structural costs and operating expenses and better align the Company’s operating structure for commercialization with a technology-centric business model, as the Company continued to explore and evaluate strategic alternatives with its third-party financial advisor.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

In the fourth quarter of 2024, in an effort to conserve cash and in light of the shifting landscape following the United States (“U.S.”) presidential election, the Company made the decision to halt construction of the steam plant in Plains, Texas (the “Texas Steam Plant”) and close its research and development (“R&D”) facility in Lancaster, California. Furthermore, in December 2024, after completing value engineering for the next phase of the commercial-scale concentrated solar energy facility to be built in Mojave, California (the “Capella Project”), Heliogen and Woodside Energy USA Inc. (“Woodside”) decided not to pursue construction of the facility due to escalated costs.

The Company is continuing to explore additional cost saving opportunities, while also engaging with a financial advisor to explore and evaluate strategic transactions, which could include, among other things, acquisitions, divestitures, a merger or sale and partnerships. No assurance can be given that any future strategic transactions will be completed on terms that are satisfactory to the Company.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in our unaudited consolidated financial statements and the accompanying notes. Despite our intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions.

Note 2—Revenue

Disaggregated Revenue

The following table provides information about disaggregated revenue:


	Three Months Ended
	March 31,
$ in thousands		2025		2024
Project revenue		$	—	$	533
Engineering services revenue		—		421
Total services revenue		—		954
Grant revenue		—		574
Total revenue		$	—	$	1,528

During the three months ended March 31, 2025, the Company did not recognize any revenue or cost of revenue, as it did not have any active revenue generating projects at the time. The Company continues to undergo a significant transition as it prioritizes commercial deployment of its energy solutions with a technology-centric business model.

Services Revenue

Project revenue recognized during the three months ended March 31, 2024 was associated with a commercial-scale demonstration agreement (“CSDA”) the Company entered into with Woodside in March 2022 for the Capella Project. In the fourth quarter of 2024, after completing value engineering for the next phase of the Capella Project, Heliogen and Woodside decided not to pursue construction of the facility due to escalated costs. Effective December 2024, the CSDA was terminated and the Capella Project was canceled. At that time the Company had no remaining performance obligations under the CSDA.

Engineering services revenue recognized during the three months ended March 31, 2024 was associated with engineering studies and projects in the U.S. and Europe.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Grant Revenue

Grant revenue recognized during the three months ended March 31, 2024 was for costs incurred during the period to support the Capella Project that were reimbursable under an award received from the U.S. Department of Energy (the “DOE Award”). Effective December 2024, the Capella Project was canceled and as a result, the Company began the process to close out the DOE Award, which is still underway as of March 31, 2025.

Contract Estimates

No provision for contract losses was recognized during the three months ended March 31, 2024. We amortized $0.8 million during the three months ended March 31, 2024 of the previously recognized contract loss provisions as a reduction to cost of services revenue incurred during the periods based on percentages of completion.

Performance Obligations

Revenue recognized under contracts with customers, which excludes amounts to be received from government grants, relates solely to the performance obligations satisfied during the three months ended March 31, 2024 with no revenue recognized from performance obligations satisfied in prior periods. As of March 31, 2025, we had no outstanding performance obligations.

Receivables

Receivables consisted of the following:


$ in thousands	March 31, 2025		December 31, 2024



Trade receivables	$	745	$	737
Grant receivables:
Billed	—		151
Unbilled	—		377

Total grant receivables	—		528

Other receivables	179		215
Total receivables	924		1,480
Allowance for credit losses	(745)		(716)
Total receivables, net	$	179	$	764

Customer Concentrations

The following table shows the customers, including governmental entities, who accounted for greater than 10% of our total revenue:


	Three Months Ended
	March 31,
		2025		2024
Customer A		—	%	57	%
Customer B		—	%	38	%

The following table shows the customers, including governmental entities, who accounted for greater than 10% of our total receivables:


	March 31, 2025		December 31, 2024

Customer B	—	%	69	%

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Note 3—Warrants

Public Warrants and Private Warrants

The Company’s warrant liabilities as of March 31, 2025 include public warrants (the “Public Warrants”) and private placement warrants (the “Private Warrants,” and together with the Public Warrants, the “Public and Private Warrants”). The Public Warrants and Private Warrants permit warrant holders to purchase in the aggregate 238,095 shares and 6,667 shares, respectively, of the Company’s common stock at an exercise price of $402.50 per share. The Public and Private Warrants became exercisable on March 18, 2022 and expire on December 30, 2026, or earlier upon redemption or liquidation. The Public and Private Warrants are recorded as liabilities on the consolidated balance sheets and measured at fair value at each reporting date, with the change in fair value included in gain (loss) on warrant remeasurement on the consolidated statements of operations.

The Company’s Public and Private Warrants are measured at fair value on a recurring basis summarized in the following table by fair value measurement level:


$ in thousands	Level	March 31, 2025		December 31, 2024


Liabilities:
Public Warrants (1)	1	$	37	$	34
Private Warrants (1)	2	1		1

________________

(1)Included in other long-term liabilities on the consolidated balance sheets.

Private Warrants. The fair value of the Private Warrants approximates the fair value of the Public Warrants due to the existence of similar redemption provisions. As a result, the Company has determined that the fair value of the Private Warrants at a specific date would be similar to that of the Public Warrants, and thus the fair value is determined by using the closing price of the Public Warrants, which was $0.004 as of March 31, 2025.

Project Warrants

In connection with the execution of the CSDA with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase 26,068 shares of the Company’s common stock at an exercise price of $0.35 per share (the “Project Warrants”). The Project Warrants expire upon the earlier of a change of control of the Company or March 28, 2027 and vest pro rata with certain payments required to be made by Woodside under the CSDA. The fair value of the Project Warrants upon issuance was $173.60 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price. The Project Warrants are recorded as equity on the consolidated balance sheets.

The Company recognizes additional paid-in capital related to the Project Warrants to reflect the attribution of the Project Warrants’ fair value in a manner similar to revenue recognized under the CSDA. In December 2024, the CSDA was terminated and as a result, vesting of the Project Warrants ceased. During the three months ended March 31, 2024, $0.1 million was recognized as additional paid-in capital related to the vesting of Project Warrants. As of March 31, 2025, vested Project Warrants were exercisable for 15,168 shares of the Company’s common stock.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Collaboration Warrants

In connection with the execution of a collaboration agreement (the “Collaboration Agreement”) with Woodside in March 2022, the Company issued warrants permitting Woodside to purchase 104,275 shares of the Company’s common stock at an exercise price of $0.35 per share (the “Collaboration Warrants”). Under the Collaboration Agreement, Woodside will assist us in defining product offerings that use our modular technology for potential customers. The Collaboration Warrants expire upon the earlier of a change of control of the Company or March 28, 2027. Of these warrants, (i) half of the warrants vested immediately upon execution of the Collaboration Agreement, to purchase 52,138 shares of the Company’s common stock and (ii) the remaining warrants will vest based on certain specified performance goals under the Collaboration Agreement. The fair value of the Collaboration Warrants upon issuance was $173.60 per warrant based on the closing price of the Company’s common stock on March 28, 2022, less the exercise price. The Collaboration Warrants are recorded as equity on the consolidated balance sheets.

Note 4—Property, Plant and Equipment

Major classes of property, plant and equipment, consisted of the following:


$ in thousands	Estimated Useful Lives in Years	March 31, 2025		December 31, 2024
Leasehold improvements	5 — 7	$	36	$	36
Computer equipment	2 — 3	2,003		2,019
Machinery, vehicles and other equipment	5 — 7	185		504
Furniture and fixtures	2	174		321

Total property, plant and equipment		2,398		2,880
Accumulated depreciation		(2,261)		(2,565)
Total property, plant and equipment, net		$	137	$	315

Depreciation expense for property, plant and equipment was $24 thousand and $0.4 million for the three months ended March 31, 2025 and 2024, respectively, and is recorded in selling, general and administrative (“SG&A”) expense with a portion allocated to cost of services revenue.

Asset Sales

During the second quarter of 2024, we began to sell assets, which were primarily located at our Manufacturing Facility as a result of the decision to close the facility. During the three months ended March 31, 2025, we received $54 thousand in proceeds from the sale of property, plant and equipment and recognized a loss of $0.1 million from disposal of assets, which is recorded in SG&A expense.

Note 5—Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:


$ in thousands	March 31, 2025		December 31, 2024
Payroll and other employee benefits	$	506	$	1,431
Professional fees	477		1,116
Research, development and project costs	5,053		5,616

Operating lease liabilities, current portion	974		2,550
Other accrued expenses	391		451
Total accrued expenses and other current liabilities	$	7,401	$	11,164

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Note 6—Leases

The Company has operating leases, primarily for real estate. There are no material residual value guarantees associated with any of the Company’s operating leases.

Pasadena, California. On May 23, 2021, we executed a seven-year lease for office space in Pasadena, California (the “Pasadena Office Lease”). The Pasadena Office Lease includes an early termination option at no cost, which we intend to exercise on May 31, 2026. During the three months ended March 31, 2025, we performed an impairment assessment of our Pasadena Office Lease due to continued workforce reductions and a decline in the market for subleases as the lease termination nears. We determined that the carrying value of the Pasadena Office Lease exceeded the fair value of the respective remaining lease term and recorded a right-of-use asset impairment of $0.9 million, which is included in impairment and other charges on our consolidated statements of operations.

Long Beach, California. Effective July 27, 2021, we executed a lease for manufacturing space in Long Beach, California (the “Long Beach Lease”) for five years. As security for the Company’s faithful performance of its obligations under the Long Beach Lease, a commercial bank issued an unconditional and irrevocable $1.5 million standby letter of credit payable to the lessor. Effective February 18, 2025, we executed a lease termination agreement for the Long Beach Lease, which resulted in a one-time termination fee of $0.8 million. In connection with the lease termination, the Company removed the remaining $1.5 million right-of-use asset and $2.8 million operating lease liabilities for the Long Beach Lease, and recognized a gain on termination of lease of $0.5 million. Further, pursuant to the terms of the lease termination, the cash collateralized $1.5 million standby letter of credit was released to the Company in March 2025.

The following table provides information on the amounts of our right-of-use assets and liabilities included on our consolidated balances sheets:


$ in thousands	Financial Statement Line	March 31, 2025		December 31, 2024
Operating lease right-of-use assets	Operating lease right-of-use assets	$	146	$	2,831

Operating lease liabilities, current	Accrued expenses and other current liabilities	974		2,550
Operating lease liabilities, non-current	Operating lease liabilities, non-current	730		2,314

The weighted-average remaining lease terms and discount rates for the Company’s operating leases were as follows:


	March 31, 2025		December 31, 2024
Weighted-average remaining lease term (years)	3.5		2.5
Weighted-average discount rate	10.5	%	8.4	%

The following table summarizes the supplemental cash flow information related to leases:


	Three Months Ended
	March 31,
$ in thousands	2025		2024
Cash paid for amounts included in the measurement of operating lease liabilities	$	441	$	690
Right-of-use assets obtained in exchange for new operating lease liabilities	—		132
Right-of-use assets removed upon lease termination	1,494		—

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

As of March 31, 2025, the maturities of our future undiscounted cash flows associated with our operating lease liabilities were as follows:


$ in thousands
2025 (remaining months)	$	803
2026	603
2027	109
2030	111
2031	112
Thereafter	437
Total future lease payments	$	2,175
Less: Imputed interest	(471)
Present value of future lease payments	$	1,704

Note 7—Equity

Stockholders Rights Plan

On April 16, 2025, the Company entered into Amendment No. 3 to the Rights Agreement, dated as of April 16, 2023, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (as amended by that certain Amendment No. 1, dated as of April 16, 2024, and by that certain Amendment No. 2 dated as of December 17, 2024, the “Rights Agreement”) to extend the expiration date of the Rights Agreement until April 17, 2026, unless the Rights (as defined below) are earlier redeemed or exchanged by the Company. Under the Rights Agreement, the Company’s Board of Directors (the “Board”) declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of the Company’s common stock to the stockholders of record as of the close of business on April 28, 2023, and adopted a limited duration stockholder rights plan. The Rights will be exercisable only if a person or group (an “acquiring person”) acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of 12.5% or more of the Company’s outstanding common stock (20% for certain passive institutional investors as described in the Rights Agreement) without the approval of the Board. Once the Rights become exercisable, each Right will entitle its holder (other than the acquiring person, whose rights will become void) to purchase for $26.40, subject to adjustment, additional shares of our common stock having a market value of twice such exercise price. In addition, the Rights Agreement has customary flip-over and exchange features.

Amendment No. 1 to the Rights Agreement, amended the definition of “acquiring person” to reflect the terms and conditions of the limited waiver previously granted by us to Nant Capital, LLC and certain of its affiliates, as previously disclosed on the Company’s Current Report on Form 8-K dated February 15, 2024.

The Rights Agreement will reduce the likelihood that any entity, person or group gains control of Heliogen through open market accumulation without paying all stockholders an appropriate control premium or without providing our Board sufficient time to make informed judgments and take actions that are in the best interests of all stockholders.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Note 8—Earnings (Loss) per Share

The calculation of basic and diluted earnings (loss) per share (“EPS”) were as follows:


	Three Months Ended
	March 31,
$ in thousands, except share and per share data		2025		2024
Numerator:
Net loss		$	(6,359)	$	(15,225)
Denominator:
Weighted-average common shares outstanding		6,099,299		5,952,672
Weighted-average impact of warrants (1)		70,788		68,320
Denominator for basic EPS – weighted-average shares		6,170,087		6,020,992
Effect of dilutive securities		—		—
Denominator for diluted EPS – weighted-average shares		6,170,087		6,020,992

EPS – Basic and Diluted		$	(1.03)	$	(2.53)

________________

(1)Warrants that have a $0.35 exercise price per common share are assumed to be exercised when vested because common shares issued for little consideration upon exercise are included in outstanding shares for the purposes of computing basic and diluted EPS.

The following securities were excluded from the calculation of EPS as their impact would be anti-dilutive:


	Three Months Ended
	March 31,
		2025	2024
Stock options		136,351	184,254
Shares issuable under the employee stock purchase plan		11,225	10,149
Unvested restricted stock units		362,591	278,242
Unvested warrants		63,037	64,530
Vested warrants		244,762	244,762

Note 9—Share-based Compensation

The Heliogen, Inc. 2021 Equity Incentive Plan aims to incentivize employees, directors and consultants who render services to the Company through the granting of stock awards, including stock options, stock appreciation right awards, restricted stock awards, restricted stock unit (“RSU”) awards, performance awards, and other stock-based awards.

The following table summarizes our share-based compensation expense by the affected line on our consolidated statements of operations:


	Three Months Ended
	March 31,
$ in thousands		2025		2024
Cost of services revenue		$	—	$	47
Selling, general and administrative		459		878
Research and development		(53)		361
Total share-based compensation expense		$	406	$	1,286

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

The following table summarizes our share-based compensation expense by grant type:


	Three Months Ended
	March 31,
$ in thousands		2025		2024
Stock options		$	68	$	129
Restricted stock units		335		1,148
Employee stock purchase plan		3		9

Total share-based compensation expense		$	406	$	1,286

Stock Options

The following table summarizes the Company’s stock option activity:


$ in thousands, except share and per share data	Number of Shares	Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value ($)





Outstanding balance as of December 31, 2024	162,927	$	9.64	3.95	$	—


Forfeited	(432)	67.16
Expired	(26,144)	6.30
Outstanding balance as of March 31, 2025	136,351	$	10.10	3.91	$	—
Exercisable as of March 31, 2025	136,254	$	10.05	3.91	$	—

Restricted Stock Units

The following table summarizes the Company’s RSU award activity:


	Number of Shares	Weighted Average Grant Date Fair Value ($)
Unvested as of December 31, 2024	458,495	$	11.97

Vested	(31,205)	30.77
Forfeited	(64,699)	9.45
Unvested as of March 31, 2025	362,591	$	10.80

As of March 31, 2025, the unrecognized compensation cost related to unvested RSU awards was $1.9 million which is expected to be recognized over a weighted-average period of 1.8 years.

Note 10—Impairment and Other Charges

Impairment and other charges consisted of the following:


	Three Months Ended
	March 31,
$ in thousands		2025		2024
Operating lease right-of-use asset		$	861	$	—
Manufacturing Facility closing costs		112		—
Severance costs		182		32
Total impairment and other charges		$	1,155	$	32

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Right-of-Use Asset Impairment

During the three months ended March 31, 2025, we recorded a right-of-use asset impairment of $0.9 million associated with the Pasadena Office Lease. Refer to Note 6—Leases—Pasadena, California for additional information.

Manufacturing Facility Closure

In May 2024, the Company made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of its Manufacturing Facility and a reduction in third-party costs. These actions were intended to further reduce structural costs and operating expenses and better align the Company’s operating structure for commercialization with a technology-centric business model. Costs and charges related to the implementation of the Company’s targeted plan, were accrued when probable and reasonably estimable or at the time of program announcement.

During the three months ended March 31, 2025, the Company incurred $0.1 million of costs associated with the lease termination in connection to the targeted plan, bringing the total impairment and other charges incurred since May 2024 to $5.2 million. Refer to Part II, Item 8, Note 13—Impairments and Other Charges—Manufacturing Facility Closure in our Annual Report for additional information about the impairment and other charges recorded during the year ended December 31, 2024.

As of December 31, 2024, the Company had a liability of $0.3 million associated with closing the Manufacturing Facility, which was included in accrued expenses and other current liabilities on our consolidated balance sheets and was fully paid on the effective date of the Long Beach Lease termination in February 2025.

Reorganization Costs

During the three months ended March 31, 2025 and 2024, we recorded severance costs of $0.2 million and $32 thousand, respectively, related to employee severance and related benefits. As of March 31, 2025, we had $0.3 million accrued for employee severance and related benefits, which is included in accrued expenses and other current liabilities on our consolidated balance sheets.

Note 11—Income Taxes

We calculate our quarterly tax provision pursuant to the guidelines in Accounting Standards Codification (“ASC”) 740, Income Taxes. ASC 740 requires companies to estimate the annual effective tax rate for current year ordinary income. The estimated annual effective tax rate represents the Company’s estimate of the tax provision in relation to the best estimate of pre-tax ordinary income or loss. The estimated annual effective tax rate is then applied to year-to-date ordinary income or loss to calculate the year-to-date interim tax provision. The relationship between our income tax provision or benefit and our pre-tax book income or loss can vary significantly from period to period considering, among other factors, the overall level of pre-tax book income or loss and changes in the blend of jurisdictional income or loss that is taxed at different rates and changes in valuation allowances. The income tax provision was $2 thousand and $2 thousand for the three months ended March 31, 2025 and 2024, respectively. Any income tax benefit associated with the pre-tax loss for the three months ended March 31, 2025 and 2024, resulting primarily from the U.S. jurisdiction, is offset by a full valuation allowance.

The Company is under audit by the Internal Revenue Services for the year ended December 31, 2022. We believe that we have made adequate provision for all income tax uncertainties.

Table of Contents

Heliogen, Inc.

Notes to the Unaudited Consolidated Financial Statements

Note 12—Commitments and Contingencies

From time to time, we are involved in various claims and lawsuits arising in the normal course of business, including proceedings involving tort and other general liability claims and other miscellaneous claims. We recognize a liability when we believe the loss is probable and reasonably estimable. We currently believe that the ultimate outcome of such lawsuits and proceedings will not, individually or in the aggregate, have a material effect on our unaudited consolidated financial statements as of and for the three months ended March 31, 2025.

Note 13—Segment Reporting

We manage our business on a consolidated basis and operate as one operating segment, which includes all activities related to our concentrated solar energy technology and thermal energy storage. Our chief operating decision maker (“CODM”) is our chief executive officer. The CODM reviews consolidated operating expenses, as presented on our consolidated statements of operations, to measure segment profit or loss, alongside with cash and cash equivalents, as presented on our consolidated balance sheets. In addition to the significant expense categories presented on our consolidated statements of operations, the CODM reviews the SG&A and R&D expenses on a more disaggregated level.

The CODM uses these financial metrics to allocate resources on a consolidated basis, which enables the CODM to assess both the overall level of resources available and optimize distribution of resources across functions and R&D programs in line with our long-term strategic goals. The CODM does not evaluate our operating segment using total assets information.

The following table provides information about disaggregated SG&A expenses:


	Three Months Ended
	March 31,
$ in thousands	2025		2024
Employee compensation, excluding share-based compensation	$	2,247	$	4,211
Share-based compensation	459		878
Other selling, general and administrative (1)	1,932		7,266
Total selling, general and administrative	$	4,638	$	12,355

________________

(1)Other SG&A expense primarily consists of professional and consulting fees, facilities and other related costs and other administrative expenses.

The following table provides information about disaggregated R&D expenses:


	Three Months Ended
	March 31,
$ in thousands	2025		2024
Employee compensation, excluding share-based compensation	$	797	$	2,493
Share-based compensation	(53)		361
Other research and development (1)	344		937
Total research and development	$	1,088	$	3,791

________________

(1)Other R&D expense primarily consists of direct R&D costs, prototyping and testing expenses.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following management’s discussion and analysis (“MD&A”) provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions, including those described in “Cautionary Note Regarding Forward-Looking Statements” included in the fore-part in this Quarterly Report on Form 10-Q (our “Quarterly Report”) and included in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Annual Report”), as filed with the Securities and Exchange Commission on March 27, 2025.

The following MD&A should be read in conjunction with our unaudited consolidated financial statements and related notes included in Part I Item 1 in this Quarterly Report and our audited consolidated financial statements as of December 31, 2024, included in our Annual Report.

Overview

Heliogen, Inc. and its subsidiaries (collectively, “Heliogen,” the “Company,” “we,” “us,” or “our”) is a renewable energy technology company focused on delivering round-the-clock, low-carbon energy production, using concentrated sunlight and thermal energy storage to deliver cost-effective, load-following, high-capacity factor thermal and electric energy.

We are undergoing a significant transition to align our operating structure with a technology-centric business model, as we prioritize the commercial deployment of our energy solutions by focusing on the development and implementation of our enhanced concentrated solar energy technology and thermal energy storage. We also offer engineering, research and development (“R&D”), maintenance and project development support to third parties seeking reliable, low-carbon energy and storage solutions.

Results of Operations

We have historically incurred operating losses as we are in the early stages of commercializing our technology and investing in the R&D and infrastructure necessary to achieve our goals. However, we remain focused on achieving sufficient scale and efficiency improvements through technological progress and additional learning to ultimately achieve profitability.

Certain Factors Affecting our Financial Results

Capella Project. In March 2022, we entered into a commercial-scale demonstration agreement (“CSDA”) to engineer and construct a 5 MW commercial-scale concentrated solar energy facility (the “Capella Project”) with Woodside Energy USA Inc. (“Woodside”) in Mojave, California and received an award from the United States Department of Energy (the “DOE Award”) to support the Capella Project.

In the fourth quarter of 2023, we adjusted the Capella Project estimate after completing the front-end engineering and design phase and in January 2024, we executed a change order to the CSDA with Woodside that extended the expected completion date for the Capella Project in order to provide us more time for value engineering to explore additional cost saving and funding opportunities.

In the fourth quarter of 2024, after completing value engineering for the next phase of the Capella Project, Heliogen and Woodside decided not to pursue construction of the facility due to escalated costs. Effective December 2024, we received notice of termination of the CSDA from Woodside and the Capella Project was canceled. As a result of the cancellation of the Capella Project, we began the process to close out the DOE Award, which is still underway as of March 31, 2025. As a result, our financial statements reflect no revenue or costs of revenue during the three months ended March 31, 2025 as compared to the same period in 2024.

Manufacturing Facility Closure. In May 2024, we implemented a targeted plan, which included a workforce reduction, the closing of our manufacturing facility in Long Beach, California, (the “Manufacturing Facility”) and a reduction in third-party costs. In February 2025, we terminated the lease for the Manufacturing Facility. As a result, our financial statements reflect reductions in facility costs and operating expenses during the three months ended March 31, 2025 as compared to the same period in 2024.

Table of Contents

During the three months ended March 31, 2025, the Company incurred $0.1 million of costs associated with the lease termination in connection to the targeted plan, bringing the total impairment and other charges incurred since May 2024 to $5.2 million, which consisted of $1.2 million of costs associated with closing our Manufacturing Facility, including a right-of-use asset impairment and other related costs, $3.4 million of other asset impairment charges and $0.6 million of employee transition, severance payments and related benefits.

R&D Facility. In the fourth quarter of 2024, we closed our R&D facility in Lancaster, California. As a result, our financial statements reflect a reduction in R&D expenses during the three months ended March 31, 2025 as compared to the same period in 2024.

Texas Steam Plant. In October 2023, we executed a land lease in Plains, Texas and initiated construction on a Heliogen steam plant in the Permian Basin (the “Texas Steam Plant”). During the year ended December 31, 2024, we made progress toward mechanical completion, however, in the fourth quarter, we made the decision to halt construction of the Texas Steam Plant. As a result, our financial statements reflect a reduction in R&D expenses during the three months ended March 31, 2025 as compared to the same period in 2024.

Comparison of the Three Months Ended March 31, 2025 and 2024


	Three Months Ended
	March 31,
$ in thousands		2025		2024		$ Change		% Change
Revenue:
Services revenue		$	—	$	954	$	(954)	(100)	%
Grant revenue		—		574		(574)		(100)	%
Total revenue		—		1,528		(1,528)
Cost of revenue:
Cost of services revenue (including depreciation)		—		903		(903)		(100)	%
Cost of grant revenue		—		574		(574)		(100)	%

Gross profit		—		51		(51)

Operating expenses:
Selling, general and administrative		4,638		12,355		(7,717)		(62)	%
Research and development		1,088		3,791		(2,703)		(71)	%
Impairment and other charges		1,155		32		1,123		3,509	%
Operating loss		(6,881)		(16,127)		9,246

Interest income		300		683		(383)		(56)	%
Loss on warrant remeasurement		(3)		(24)		21		(88)	%
Other income, net		227		245		(18)		(7)	%
Net loss before taxes		(6,357)		(15,223)		8,866
Provision for income taxes		(2)		(2)		—		—	%
Net loss		$	(6,359)	$	(15,225)	$	8,866

Revenue and Gross Profit

During the three months ended March 31, 2025, we did not recognize any revenue or cost of revenue, as we did not have any active revenue generating projects at the time. We are continuing to undergo a significant transition as we prioritize commercial deployment of our energy solutions with a technology-centric business model.

Table of Contents

During the three months ended March 31, 2024, we recognized services revenue of $1.0 million, which consisted of $0.5 million of project revenue associated with the Capella Project and $0.4 million of revenue for engineering services performed during the period. During the three months ended March 31, 2024, we recognized grant revenue of $0.6 million for costs incurred during the period to support the Capella Project that were reimbursable under the DOE Award.

Selling, General and Administrative

The following table summarizes selling, general and administrative (“SG&A”) expenses:


	Three Months Ended
	March 31,
$ in thousands	2025		2024		$ Change
Employee compensation, excluding share-based compensation	$	2,247	$	4,211	$	(1,964)
Share-based compensation	459		878		(419)
Other selling, general and administrative	1,932		7,266		(5,334)
Total selling, general and administrative	$	4,638	$	12,355	$	(7,717)

During the three months ended March 31, 2025, we recognized SG&A expense of $4.6 million, a decrease of $7.7 million compared to SG&A expense of $12.4 million for the three months ended March 31, 2024. The decrease was primarily driven by a decrease of $5.3 million in other SG&A expense primarily driven by a decrease in professional and consulting fees, facility costs and other discretionary spending as we focused on reducing third-party costs. Additionally, there was a decrease of $2.0 million in employee compensation primarily due to workforce reductions and a decrease of $0.4 million in share-based compensation expense due to forfeitures.

Research and Development

The following table summarizes R&D expenses:


	Three Months Ended
	March 31,
$ in thousands	2025		2024		$ Change
Employee compensation, excluding share-based compensation	$	797	$	2,493	$	(1,696)
Share-based compensation	(53)		361		(414)
Other research and development	344		937		(593)
Total research and development	$	1,088	$	3,791	$	(2,703)

During the three months ended March 31, 2025, we recognized R&D expense of $1.1 million, a decrease of $2.7 million compared to R&D expense of $3.8 million for the three months ended March 31, 2024. The decrease was primarily driven by a decrease of $1.7 million in employee compensation primarily due to workforce reductions, a decrease of $0.6 million in other R&D expense as we focused spending on strategic R&D projects and a decrease of $0.4 million in share-based compensation expense due to forfeitures.

Impairment and Other Charges

During the three months ended March 31, 2025, we recognized impairment and other charges of $1.2 million, consisting of a right-of-use asset impairment of $0.9 million associated with the office lease in Pasadena, California, $0.2 million of employee severance and related benefits and $0.1 million of costs associated with closing our Manufacturing Facility.

During the three months ended March 31, 2024, we recognized impairment and other charges of $32 thousand for employee severance and related benefits.

Table of Contents

Interest Income

During the three months ended March 31, 2025, we recognized interest income of $0.3 million, a decrease of $0.4 million compared to interest income of $0.7 million for the three months ended March 31, 2024. The decrease is primarily attributable to a decrease in our cash equivalent balances held in high interest yield accounts.

Liquidity and Capital Resources

Our principal sources of liquidity are cash and cash equivalents, which are short-term in duration and highly liquid, and cash receipts from customers and government grants. Our principal uses of cash are expenditures related to project development and completion, as well as R&D and SG&A expenditures in support of our technology development and operational support. As of March 31, 2025 and April 30, 2025, the Company had liquidity of $30.1 million and $28.4 million, respectively, consisting of cash and cash equivalents and no debt.

Going Concern

The accompanying financial statements have been prepared assuming we will continue as a going concern. As of March 31, 2025, our liquidity was $30.1 million and we had an accumulated deficit of $412.0 million. During the three months ended March 31, 2025, we incurred a net loss of $6.4 million and used cash in operations of $8.4 million. We expect to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on our liquidity position as of March 31, 2025 and our current forecast of operating results and cash flows, we anticipate that we may not have sufficient resources to fund our cash obligations for the next 12 months after the issuance date of this Quarterly Report. These factors raise substantial doubt about our ability to continue as a going concern. We have evaluated the conditions discussed above and we are taking various steps in an effort, to alleviate them, including the following actions.

In the second quarter of 2024, we made the strategic decision to implement a targeted plan, which included a workforce reduction, the closing of our Manufacturing Facility, and a reduction in third-party costs. In February 2025, we terminated the lease for the Manufacturing Facility. These actions were intended to further reduce structural costs and operating expenses and better align our operating structure for commercialization with a technology-centric business model.

In the fourth quarter of 2024, in an effort to conserve cash and in light of the shifting landscape following the United States presidential election, we made the decision to halt construction of our Texas Steam Plant and close our R&D facility. Furthermore, in December 2024, after completing value engineering for the next phase of the Capella Project, Heliogen and Woodside decided not to pursue construction of the facility due to escalated costs.

We plan to continue to explore cost saving opportunities, while also engaging with a financial advisor to explore and evaluate strategic transactions, which could include, among other things, acquisitions, divestitures, a merger or sale and partnerships.

No assurance can be given that any future strategic transactions will be completed on terms that are satisfactory to us, if at all. If we are unable to effectively implement any of our plans, we may be forced to delay, reduce or eliminate more of our commercialization efforts, product expansion or R&D programs and our business, financial condition and results of operations could be materially and adversely affected. Assuming no additional funding and based on our current operating and development plans, we expect that existing liquidity as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second quarter of 2026.

Table of Contents

Summary of Cash Flows

The following table provides a summary of our cash flows:


	Three Months Ended
	March 31,
$ in thousands	2025		2024
Net cash used in operating activities	$	(8,430)	$	(14,313)
Net cash provided by investing activities	54		9,850
Net cash used in financing activities	(9)		(17)

Net Cash from Operating Activities. Net cash used in operating activities was $8.4 million for the three months ended March 31, 2025 compared to net cash used in operating activities of $14.3 million for the three months ended March 31, 2024. The $5.9 million decrease in the net cash used in operating activities was primarily driven by reductions in headcount and discretionary spending as we focused on cost saving opportunities.

Net Cash from Investing Activities. Net cash provided by investing activities was $54 thousand for the three months ended March 31, 2025 compared to net cash provided by investing activities of $9.9 million for the three months ended March 31, 2024. For the three months ended March 31, 2025, we received proceeds from the sale of property, plant and equipment of $54 thousand. For the three months ended March 31, 2024, we received proceeds from the maturities of available-for-sale securities of $10.0 million, partially offset by capital expenditures of $0.2 million.

Net Cash from Financing Activities. Net cash used in financing activities was $9 thousand and $17 thousand for the three months ended March 31, 2025 and 2024, respectively, related to taxes for net-share settlement of share-based compensation.

Cash Requirements

Our material cash requirements from known contractual and other obligations consist of our long-term operating leases, which are primarily for real estate. Refer to Note 6—Leases for additional information regarding maturity analysis of our operating leases.

Critical Accounting Estimates

There have been no material changes to our discussion of critical accounting estimates from those set forth in our Annual Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, and as a result of the material weaknesses in our internal control over financial reporting described in our Annual Report, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2025, our disclosure controls and procedures were not effective.

Table of Contents

Changes in Internal Control over Financial Reporting

Other than executing upon the implementation of the remediation measures described in our Annual Report and the associated changes to our internal control over financial reporting, there were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II - Other Information

Item 1. Legal Proceedings

Information relating to various commitments and contingencies is described in Note 12—Commitments and Contingencies to our unaudited consolidated financial statements in Part I, Item 1 of this Quarterly Report.

Item 1A. Risk Factors

There are no material changes from the risk factors previously disclosed in Part I, Item 1A. Risk Factors in our Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

Trading Arrangements

During the three months ended March 31, 2025, none of the Company’s directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

Table of Contents

Item 6. Exhibits

Exhibit Number

Description

Incorporated by Reference

Form

File No.

Exhibit

Filing Date

3.1

Second Amended and Restated Certificate of Incorporation of Heliogen, Inc.

8-K

001-40209

3.1

January 6, 2022

3.2

Certificate of Amendment of Certificate of Incorporation of Heliogen, Inc., dated August 31, 2023.

8-K

001-40209

3.1

August 31, 2023

3.3

Second Amended and Restated Bylaws of Heliogen, Inc.

10-Q

001-40209

3.2

November 8, 2022

3.4

Certificate of Designations of Series A Junior Participating Preferred Stock of Heliogen, Inc.

8-K

001-40209

3.1

April 17, 2023

4.1

Rights Agreement, dated as of April 16, 2023, between Heliogen, Inc. and Continental Stock Transfer & Trust Company, as rights agent.

8-K

001-40209

4.1

April 17, 2023

4.2

Amendment No. 1, dated as of April 16, 2024, to Rights Agreement, dated as of April 16, 2023, by and between Heliogen, Inc. and Continental Stock Transfer & Trust Company, as rights agent.

8-K

001-40209

4.1

April 16, 2024

4.3

Amendment No. 2, dated as of December 17, 2024, to Rights Agreement, dated as of April 16, 2023, by and between Heliogen, Inc. and Continental Stock Transfer & Trust Company, as rights agent.

8-K

001-40209

4.1

December 17, 2024

4.4

Amendment No. 3, dated as of April 15, 2025, to Rights Agreement, dated as of April 16, 2023, by and between Heliogen, Inc. and Continental Stock Transfer & Trust Company, as rights agent.

8-K

001-40209

4.1

April 15, 2025

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following information from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Unaudited Consolidated Financial Statements.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

________________

* Filed herewith.

** Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May 7, 2025.


						Heliogen, Inc.

			By:			/s/ Christiana Obiaya
						Christiana Obiaya
						Chief Executive Officer (Principal Executive Officer)

			By:			/s/ Phelps Morris
						Phelps Morris
						Chief Financial Officer (Principal Financial Officer)